ARCHIVES

Enzalutamide Reduced Risk of Progression By 81 Percent in Metastatic Prostate Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Approves Afinitor For pNET; No Word On Sutent For Same Use

May 6, 2011

In Brief: Columbia’s Marks Reportedly Will Move To MSK; FDA Committee to Consider THC For Group C List

May 23, 1980

New Publications

January 20, 1989

Three-Quarters of P01 $$ Goes To Translational Grants, NCI Finds

October 2, 1992

Aventis, MediGene In Pact For Development Of Vaccine.

February 25, 2000

In Brief: FASEB Letter urges Support Of NIH, NSF; Kansas Recruits Experts From Washington State

July 30, 1993